CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

Discover why CVS' turnaround may be underway with improved medical cost trends, segment growth, and raised FY2025 guidance.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

CVS Health’s insurance division Aetna will stop offering plans for individuals on the Affordable Care Act exchanges in 2026, after the company projected big losses in the business this year.

Boosted by Microsoft's offerings, CVS intends to accelerate ... Expanding digital means CVS plans to improve its omnichannel pharmacy capabilities using Microsoft tools to provide personalised ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.